Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
von Willebrand factor Ristocetin co-factor activity to von Willebrand factor antigen level ratio for diagnosis of acquired von Willebrand syndrome caused by aortic stenosis.
Okubo N, Sugawara S, Fujiwara T, Sakatsume K, Doman T, Yamashita M, Goto K, Tateishi M, Suzuki M, Shirakawa R, Eura Y, Kokame K, Hayakawa M, Matsumoto M, Kawate Y, Miura M, Takiguchi H, Soga Y, Shirai S, Ando K, Arai Y, Nakayoshi T, Fukumoto Y, Takahama H, Yasuda S, Tamura T, Watanabe S, Kimura T, Yaoita N, Shimokawa H, Saiki Y, Kaikita K, Tsujita K, Yoshii S, Nakase H, Fujimaki SI, Horiuchi H. Okubo N, et al. Among authors: tateishi m. Res Pract Thromb Haemost. 2023 Nov 30;8(1):102284. doi: 10.1016/j.rpth.2023.102284. eCollection 2024 Jan. Res Pract Thromb Haemost. 2023. PMID: 38268521 Free PMC article.
Pretreatment Fibrinogen Level Is a Prognostic Factor for Esophageal Cancer Patients Who Receive Curative Treatment.
Aoyama T, Kato A, Hashimoto I, Maezawa Y, Hara K, Kawahara S, Kazama K, Komori K, Yoshizawa S, Tamagawa A, Tateishi M, Minami T, Cho H, Morita J, Otani K, Sawazaki S, Numata M, Tanabe M, Oshima T, Saito A, Yukawa N, Rino Y. Aoyama T, et al. Among authors: tateishi m. Anticancer Res. 2024 Jan;44(1):249-255. doi: 10.21873/anticanres.16808. Anticancer Res. 2024. PMID: 38159985
An ADAM17 selective inhibitor promotes glucose uptake by activating AMPK.
Toma T, Miyakawa N, Tateishi M, Todaka M, Kondo T, Fujita M, Otsuka M, Araki E, Tateishi H. Toma T, et al. Among authors: tateishi m. J Pharmacol Sci. 2024 Jan;154(1):37-46. doi: 10.1016/j.jphs.2023.11.005. Epub 2023 Dec 1. J Pharmacol Sci. 2024. PMID: 38081682 Free article.
The Clinical Influence of Geriatric Nutritional Risk Index in Patients With Gastric Cancer Who Receive Curative Treatment.
Aoyama T, Maezawa Y, Hashimoto I, Hara K, Kazama K, Numata M, Sawazaki S, Tamagawa H, Tamagawa A, Nakazono M, Segami K, Cho H, Tateishi M, Minami T, Nagasawa S, Komori K, Kato A, Otani K, Kawahara S, Oshima T, Yukawa N, Saito A, Rino Y. Aoyama T, et al. Among authors: tateishi m. Anticancer Res. 2023 Dec;43(12):5605-5612. doi: 10.21873/anticanres.16763. Anticancer Res. 2023. PMID: 38030197
[Participation/Dispatch Reports on the 79th Annual Meeting].
Kobayashi D, Nishigami R, Fukushima K, Tateishi M, Seo T, Hizukuri K, Koda R, Kita K, Dang Quoc S, Mitsushima K, Kodama T, Kumamoto J, Kotani H, Oshiro T. Kobayashi D, et al. Among authors: tateishi m. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2023;79(8):870-885. doi: 10.6009/jjrt.2023-2233. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2023. PMID: 37599073 Free article. Japanese. No abstract available.
Risk factors associated with relapse after methotrexate dose reduction in patients with rheumatoid arthritis receiving golimumab and methotrexate combination therapy.
Kitamura N, Kobayashi H, Nagasawa Y, Sugiyama K, Tsuzuki H, Tanikawa Y, Ikumi N, Okada Y, Takahashi Y, Asai S, Tamura N, Ogasawara M, Kawamoto T, Kuwatsuru R, Tamaki H, Kidoguchi G, Tateishi M, Kimura M, Mochida Y, Harigane K, Shimazaki T, Koike T, Tanimura K, Kataoka H, Amano K, Yasuoka H, Takei M. Kitamura N, et al. Among authors: tateishi m. Int J Rheum Dis. 2023 Jun;26(6):1058-1066. doi: 10.1111/1756-185X.14695. Epub 2023 Apr 14. Int J Rheum Dis. 2023. PMID: 37058849
229 results